证券代码：300583 证券简称：赛托生物 公告编号:2023-053 山东赛托生物科技股份有限公司 关于召开 2023 年第二次临时股东大会的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 山东赛托生物科技股份有限公司（以下简称"公司"）第三届董事会第十九 次会议决定于 2023 年 8 月 16 日（星期三）召开 2023 年第二次临时股东大会（以 下简称 "本次股东大会"），会议通知已于 2023 年 7 月 31 日刊登于中国证监会 指定的创业板信息披露网站。现将股东大会的有关事宜提示如下： 一、召开会议的基本情况 1、股东大会届次：2023 年第二次临时股东大会 2、会议召集人：公司董事会 3、会议召开的合法、合规性：本次股东大会会议的召开符合有关法律、行 政法规、部门规章、规范性文件和《公司章程》等规定。 4、会议召开日期和时间 现场会议召开时间：2023 年 8 月 16 日（星期三）下午 14:30 网络投票时间：通过深圳证券交易所交易系统进行网络投票的时间为：2023 年 8 月 16 日 9:15-9:25，9:30-11:30 ...

Financial Performance - The company's operating revenue for the first half of 2023 reached ¥663,655,673.27, an increase of 4.31% compared to ¥636,242,960.65 in the same period last year[21]. - Net profit attributable to shareholders was ¥59,967,581.48, representing an 85.43% increase from ¥32,339,106.58 in the previous year[21]. - Basic and diluted earnings per share increased to ¥0.55, up 83.33% from ¥0.30 in the previous year[21]. - The company reported a significant increase in net profit after deducting non-recurring gains and losses, which reached ¥37,125,683.51, a 20.73% increase from ¥30,750,102.42 in the previous year[21]. - The company achieved a net profit of CNY 59,967,581.48 for the first half of 2023, with a parent company net profit of CNY 40,670,451.84[116]. - The company reported a total comprehensive income of CNY 63,455,115.72 for the first half of 2023, compared to CNY 30,385,506.16 in the previous year[199]. - The company's revenue for the reporting period reached ¥663,655,673.27, representing a year-on-year increase of 4.31% compared to ¥636,242,960.65 in the same period last year[58]. - The gross profit margin for steroid drug raw materials was 29.15%, showing an increase of 4.95% year-on-year[61]. Cash Flow and Assets - The net cash flow from operating activities was negative at -¥117,369,579.22, a decline of 164.23% compared to ¥182,721,185.87 in the same period last year[21]. - Cash and cash equivalents increased by 190.15% to ¥196,875,958.76, up from ¥67,853,561.20, primarily due to the influx of funds from the capital increase[58]. - The company's total assets as of June 30, 2023, were ¥3,506,106,963.83, reflecting a growth of 17.04% from ¥2,995,140,143.52 at the end of the previous year[22]. - The company's current assets reached CNY 1,625,846,289.28 as of June 30, 2023, compared to CNY 1,139,941,599.15 at the beginning of the year, indicating a rise of about 42.6%[191]. - The total liabilities increased to CNY 1,421,629,861.62 from CNY 1,224,800,344.70, reflecting a growth of approximately 16.1%[193]. - The company's equity attributable to shareholders rose to CNY 2,027,241,953.83 as of June 30, 2023, up from CNY 1,720,136,902.94, marking an increase of around 17.8%[193]. Investments and Projects - The company plans to distribute 6 new shares for every 10 shares held, utilizing capital reserves[6]. - Research and development investment increased by 41.91% to ¥27,913,511.71, up from ¥19,670,389.92, aimed at accelerating project progress[58]. - The total investment during the reporting period was CNY 59,966,853.47, representing a 20.09% increase compared to CNY 49,933,124.73 in the same period last year[70]. - The company has committed to producing 180 tons of dihydroxy yellow ketone, with ongoing developments in this area[84]. - The company plans to invest 270 million yuan into a new project for steroid intermediates and raw materials, with a total investment of 450.91 million yuan[90]. Market Position and Strategy - The company operates in the pharmaceutical manufacturing industry, focusing on steroid drugs, and is positioned in the upper-middle stream of the pharmaceutical supply chain[32]. - The company is actively pursuing international market expansion, evidenced by the issuance of a European pharmacopoeia suitability certificate for one of its raw materials[38]. - The company has established long-term strategic partnerships with major pharmaceutical companies, enhancing its market position and brand recognition[53]. - The company is focused on upgrading its entire industry chain, linking intermediates, raw materials, and formulations to improve cost and quality control[55]. - The company is committed to enhancing its research and development capabilities to maintain a leading position in the industry[106]. Environmental Compliance - The company emphasizes environmental protection and has implemented measures to comply with strict safety and environmental regulations[107]. - The company has implemented a wastewater treatment system that combines advanced physical and chemical processes, including multi-effect evaporation and Fenton oxidation, to ensure compliance with environmental standards[124]. - The company has classified and treated exhaust gases from various processes using methods such as alkaline spraying and catalytic oxidation, ensuring stable emissions that meet regulatory standards[125]. - The company has established a comprehensive waste management system, including separate storage for hazardous waste and measures to prevent leakage[126]. - The company has committed to zero emissions of various industrial solid wastes, ensuring no discharge into the external environment[128]. Shareholder Information - The company plans to increase its total share capital by 71,138,297 shares through a capital reserve transfer, resulting in a total share capital of 189,702,126 shares[116]. - The total number of shares outstanding is now 118,563,829, with 104,387,067 shares being unrestricted[169]. - The largest shareholder, Shandong Runxin Investment Co., Ltd., holds 22.82% of the shares, totaling 27,060,864 shares[179]. - The company has a six-month lock-up period for the newly issued shares[176]. - The company’s major shareholders have pledged a significant portion of their shares, with the first major shareholder pledging 80% of their holdings[181].

证券代码：300583 证券简称：赛托生物 山东赛托生物科技股份有限公司 投资者关系活动记录表 编号：DY2023-001 □特定对象调研 □分析师会议 □媒体采访 业绩说明会 投 资 者关 系 活 动类别 □新闻发布会 □路演活动 □现场参观 □其他 参 与 单位 名 称 及人员姓名 参与公司 2022 年度业绩网上说明会活动的投资者 时间 2023 年 5 月 5 日 15:00-17:00 地点 "全景•路演天下"平台（http://ir.p5w.net） "价值在线"平台（www.ir-online.cn） 董事长米奇先生 总经理靳连标先生 上 市 公司 接 待 人员姓名 董事、副总经理、董事会秘书李璐女士 财务总监李福文先生 独立董事卿北军先生 公司于 2023 年 5 月 5 日 15:00-17:00 在"全景•路演天下" （http://rs.p5w.net）和"价值在线"（www.ir-online.cn）举办 2022 年度业绩网上说明会，本次业绩说明会采用网络远程的方式举 行，问答环节主要内容如下： 投 资 者关 系 活 动 主 要内 容 介 绍 1、问：董事长你好，去年出台了十四五规划 ...

Financial Performance - The company's revenue for Q1 2023 was CNY 334,785,915.82, representing a 31.99% increase compared to CNY 253,646,857.08 in the same period last year[4] - Net profit attributable to shareholders for Q1 2023 was CNY 15,355,110.28, up 20.53% from CNY 12,739,991.21 in Q1 2022[4] - The company's operating profit was ¥19,947,417.76, an increase of 42% from ¥14,066,025.89 in the same period last year[26] - Net profit for Q1 2023 was ¥17,525,308.93, representing a 49% increase compared to ¥11,721,511.57 in Q1 2022[26] - Total operating revenue for Q1 2023 reached ¥334,785,915.82, a 32% increase from ¥253,646,857.08 in Q1 2022[25] - Total operating costs amounted to ¥313,685,870.45, up 31% from ¥239,159,017.57 in the previous year[25] - The company reported a total comprehensive income of ¥15,999,364.10 for Q1 2023, compared to ¥7,060,494.22 in Q1 2022[26] Cash Flow and Liquidity - The net cash flow from operating activities increased by 16.45% to CNY 10,704,060.35, compared to CNY 9,191,765.31 in the previous year[4] - The cash inflow from operating activities for Q1 2023 was CNY 248,042,987.04, a decrease of 11.7% compared to CNY 281,019,424.09 in the previous period[28] - The total cash outflow from operating activities was CNY 237,338,926.69, down from CNY 271,827,658.78 in the previous period[28] - The cash received from sales of goods and services was CNY 239,332,850.86, a decrease from CNY 243,366,071.04 in the previous period[28] - The cash paid for purchasing goods and services was CNY 92,594,498.30, an increase from CNY 48,014,507.18 in the previous period[28] - The cash paid to employees was CNY 42,219,708.05, an increase from CNY 39,952,522.80 in the previous period[28] - The net cash outflow from investing activities was CNY -27,232,006.03, an improvement from CNY -59,898,407.34 in the previous period[29] - The cash inflow from financing activities totaled CNY 381,974,721.80, up 36.4% from CNY 280,000,000.00 in the previous period[29] - The net cash flow from financing activities was CNY 6,643,103.13, a significant decrease of 87.5% compared to CNY 53,181,054.01 in the previous period[29] - The ending balance of cash and cash equivalents was CNY 46,054,445.31, down from CNY 61,832,290.63 in the previous period[29] - The company's cash and cash equivalents increased to ¥249,546,369.14 from ¥188,398,286.35 at the beginning of the year, representing a growth of 32.4%[22] Assets and Liabilities - The total assets at the end of Q1 2023 were CNY 3,107,308,236.19, a 3.75% increase from CNY 2,995,140,143.52 at the end of the previous year[4] - Total liabilities increased to ¥1,320,411,681.70, compared to ¥1,224,242,953.13 in the previous year[24] - The company’s total liabilities increased, with accounts payable rising by 43.00% to CNY 20,851.59 million due to increased payments made via bank acceptance bills[9] - Accounts receivable rose to ¥244,889,134.78 from ¥196,565,259.17, an increase of 24.6%[22] - Inventory increased to ¥635,759,362.23 from ¥608,261,782.36, reflecting a growth of 4.5%[22] - Total equity reached ¥1,786,896,554.49, slightly up from ¥1,770,897,190.39 in Q1 2022[24] Research and Development - Research and development expenses surged by 96.16% to CNY 1,399.94 million, reflecting accelerated project advancements[12] - Research and development expenses rose to ¥13,999,442.81, a significant increase of 96% from ¥7,136,868.14 in Q1 2022[25] Shareholder Information - Total number of common shareholders at the end of the reporting period is 10,821[17] - The largest shareholder, Shandong Runxin Investment Co., Ltd., holds 25.31% of shares, totaling 27,060,864 shares[17] - The company has a total of 27,154,364 shares held by major shareholders participating in financing activities[18] Regulatory and Market Activities - The company received approval from the China Securities Regulatory Commission for a stock issuance on March 29, 2023[19] - The company plans to expand its market presence following the successful registration of new shares[19] Return on Equity - The weighted average return on equity increased to 0.89% from 0.75% in the previous year[4] - The company reported a basic earnings per share of CNY 0.14, which is a 16.67% increase from CNY 0.12 in the same quarter last year[4] - Basic and diluted earnings per share for Q1 2023 were both ¥0.14, up from ¥0.12 in Q1 2022[26]

山东赛托生物科技股份有限公司2022年年度报告全文 ...

山东赛托生物科技股份有限公司 关于举行2022年度业绩网上说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 山东赛托生物科技股份有限公司（以下简称"公司"）《2022 年年度报告》 及其摘要于 2023 年 4 月 25 日刊登在中国证监会指定的创业板信息披露网站巨潮 资讯网。为了让广大投资者进一步了解公司 2022 年年度经营情况，公司定于 2023 年 5 月 5 日（星期五）15:00-17:00 在"全景网"和"价值在线"双平台采用网 络互动的方式举办 2022 年年度业绩说明会，投资者可根据习惯和方便选择登陆 "全景•路演天下"（http://rs.p5w.net）和"价值在线"（www.ir-online.cn） 任一平台参与本次年度业绩说明会。 证券代码：300583 证券简称：赛托生物 编号：2023-030 （全景•路演天下问题征集页面二维码） （价值在线问题征集页面小程序） 敬请广大投资者提前提交您所关注的问题，便于公司在业绩说明会上对投资 者普遍关注的问题进行回答，提升此次业绩说明会的针对性。 欢迎广大投资者积极参与本次网上说 ...

山东赛托生物科技股份有限公司 2022 年第三季度报告 证券代码：300583 证券简称：赛托生物 公告编号：2022-077 山东赛托生物科技股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在 虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告 中财务信息的真实、准确、完整。 3.第三季度报告是否经过审计 □是 否 1 山东赛托生物科技股份有限公司 2022 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同 | 年初至报告期末 | 年初至报告期末比 | | --- | --- | --- | --- | --- | | | | 期增减 | | 上年同期增减 | | 营业收入（元） | 296,709,591.90 | 14.8 ...

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 636,242,960.65, representing a 2.03% increase compared to CNY 623,607,764.69 in the same period last year[23]. - The net profit attributable to shareholders of the listed company was CNY 32,339,106.58, a significant increase of 70.17% from CNY 19,003,606.57 in the previous year[23]. - The net profit after deducting non-recurring gains and losses reached CNY 30,750,102.42, marking a 376.30% increase compared to CNY 6,456,016.31 in the same period last year[23]. - Cash flow from operating activities surged to CNY 182,721,185.87, a remarkable increase of 2,024.10% from CNY 8,602,296.58 in the previous year[24]. - Basic earnings per share rose to CNY 0.30, up 66.67% from CNY 0.18 in the same period last year[24]. - Total assets at the end of the reporting period were CNY 3,219,475,133.82, an increase of 8.41% from CNY 2,969,699,298.75 at the end of the previous year[24]. - The net assets attributable to shareholders of the listed company were CNY 1,712,375,060.99, reflecting a 1.76% increase from CNY 1,682,729,774.58 at the end of the previous year[24]. - The weighted average return on net assets was 1.90%, an increase of 0.75% compared to 1.15% in the previous year[24]. Investment and Projects - The company has invested ¥35,998.80 million in the project for an annual production of 700 tons of 9-hydroxyandrostenedione, and ¥23,475.55 million in the steroid intermediates and raw materials project[78]. - The company has adjusted the investment plan, terminating the construction of the 120 tons of 4-ene and 180 tons of dihydroxyprogesterone production lines, focusing on the 700 tons of 9-hydroxyandrostenedione production line[79]. - The company has allocated ¥27,000.00 million of repurposed funds to a new project for steroid intermediates and raw materials, with a total investment of ¥45,091.00 million[79]. - The company has used ¥11,460.00 million of repurposed funds to acquire 100% equity of Runxin Thermal Power[80]. - The annual net profit expected from the "700 tons of 9-hydroxyandrostenedione, 120 tons of 4-androstenedione, and 180 tons of hydroxyprogesterone project" was originally estimated at CNY 472.17 million, but after adjustments, the average annual net profit is now projected to be CNY 159.39 million[84]. - The "steroid intermediates and raw materials project" has completed the construction of three workshops, two warehouses, and a control center, but is still pending some equipment installation due to pandemic-related delays[84]. - The completion deadline for the "steroid intermediates and raw materials project" has been extended to May 1, 2023, with partial construction completed as of June 30, 2022[84]. Subsidiaries and Equity - The subsidiary Disen Bio reported a net profit of CNY 19.85 million, contributing significantly to the company's overall performance[95]. - The subsidiary Sry Pharmaceutical achieved a net profit of CNY 8.99 million, reflecting its role in the company's profitability[95]. - The company holds 100% equity in Disen Bio and 85% in Sry Pharmaceutical, indicating strong control over its key subsidiaries[97][98]. Environmental and Social Responsibility - The company is committed to environmental protection and has invested in reducing pollution during production processes[108]. - The company emphasizes its commitment to environmental protection and sustainable development, focusing on resource efficiency and waste management[148]. - The company actively engages in social responsibility initiatives, contributing to community management and public welfare[147]. - Environmental monitoring is conducted regularly by third parties, with results publicly disclosed[143]. - The company has established an emergency response plan for environmental incidents, which has been filed with local authorities[142]. Share Capital and Stock Management - The company plans not to distribute cash dividends or issue bonus shares[6]. - The company completed the cancellation of 330,500 restricted stocks due to unmet performance targets, reducing the total share capital from 107,252,567 shares to 106,922,067 shares[22]. - The company has implemented a stock incentive plan to enhance the responsibility and mission of its management team[116]. - The stock incentive plan was approved in 2017, granting 1.322 million shares to 47 incentive targets[118]. - The company completed a wastewater treatment facility with a capacity of 4,000 m³/d in June 2016 and another with a capacity of 3,600 m³/d in February 2021[133]. Financial Management and Compliance - The company has not engaged in any entrusted financial management, derivative investments, or entrusted loans during the reporting period[90][91][92]. - The company has not sold any major assets during the reporting period, maintaining its asset base[93]. - The company has maintained transparency in information disclosure, adhering to legal and regulatory requirements[149]. - The company borrowed a total of 9,000,000 RMB from its controlling shareholder, with an interest rate of 7.00%, resulting in an interest expense of 132.42 million RMB for the period[165]. - The financial report for the first half of 2022 was not audited[195].

重要内容提示: 山东赛托生物科技股份有限公司 2022 年第一季度报告全文 证券代码：300583 证券简称：赛托生物 公告编号:2022-021 山东赛托生物科技股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不 存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度 报告中财务信息的真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增 | | --- | --- | --- | --- | | | | | 减 | | 营业收入（元） | 253,646,857.08 | 272,376,194.52 | -6.88% | | 归属于上市公司股东的净利润（元） | 12,739,9 ...

Financial Performance - The company's operating revenue for 2021 was CNY 1,202,622,703.68, representing a 31.70% increase compared to CNY 913,187,604.30 in 2020[25]. - The net profit attributable to shareholders for 2021 was CNY 36,205,360.05, a significant turnaround from a loss of CNY 179,807,242.83 in 2020, marking a 120.14% improvement[25]. - The basic earnings per share for 2021 was CNY 0.34, compared to a loss of CNY 1.68 per share in 2020, reflecting a 120.24% increase[25]. - The company achieved a revenue of 1,202.87 million yuan and a net profit of 36.21 million yuan, representing a year-on-year growth of 120.14%[62]. - The total operating revenue for 2021 was CNY 1,202.62 million, representing a 31.70% increase compared to CNY 913.19 million in 2020[72]. - The pharmaceutical manufacturing segment accounted for 97.04% of total revenue, with a year-on-year growth of 32.71%[75]. - The sales volume of steroid drug raw materials increased by 35.33% year-on-year, reaching CNY 1,063.10 million[75]. - The company achieved a gross margin of 22.82% in the pharmaceutical manufacturing sector, an increase of 10.63% compared to the previous year[75]. - The company reported a total revenue of 3,594 million CNY for the year 2021[160]. Investment and R&D - The company plans to increase R&D investment to maintain its technological leadership in the industry, while implementing strict confidentiality measures to protect core technologies[9]. - The company has invested over 200 million yuan in R&D, resulting in 42 patents, including 14 invention patents[57]. - R&D expenses reached CNY 49,730,559.44, a 10.49% increase compared to CNY 45,007,850.59 in 2020[84]. - The company is actively working on the registration and production of new high-end specialty APIs, positioning itself for future growth[64]. - The company aims to transition from intermediates to high-end specialty APIs and finished formulations, enhancing its competitive edge in the pharmaceutical sector[131]. - The company plans to increase R&D investment in 2022 to drive innovation and address industry challenges, emphasizing collaboration with key universities and research institutions[137]. Market and Product Strategy - The company aims to enhance its product structure and expand the production scale of high-end intermediates, focusing on respiratory high-end specialty raw materials[12]. - The company is committed to adjusting its product structure and improving the technical content and added value of its products through lean management and technological innovation[12]. - The company is focused on strengthening cooperation with existing customers while actively seeking new clients to ensure sustainable development[7]. - The company is positioned to cover the entire industry chain from intermediates to raw materials and formulations, enhancing its competitive advantage[41]. - The market for assisted reproductive drugs is expanding due to changing national population and fertility policies, presenting significant opportunities[36]. - The company is positioned to become a global production center for steroid hormone raw materials, with domestic production accounting for approximately one-third of the world's total output[35]. Operational Efficiency and Management - The company will optimize its organizational structure and enhance management capabilities to mitigate management risks associated with its accelerated growth[8]. - The company has implemented measures to enhance management efficiency and reduce costs, resulting in significant improvements in production quality and efficiency[67]. - The company has established a competitive R&D and production system for respiratory high-end specialty APIs, with several products ready for mass production[64]. - The company has established stable strategic partnerships with leading pharmaceutical companies, enhancing brand recognition in the industry[59]. - The company has implemented a comprehensive management optimization strategy to improve efficiency and reduce costs[50]. Environmental Commitment - The company emphasizes environmental protection and has implemented measures to reduce pollution and waste emissions in its production processes[11]. - The company is committed to environmental protection and aims to achieve zero environmental pollution incidents while enhancing its green production capabilities[136]. Risks and Challenges - The company is facing industry risks due to increasing competition and rising costs of raw materials, which may impact its performance[6]. - The company acknowledges the risk of investment project failures if market expansion is insufficient, and plans to actively explore markets to absorb new production capacity[12]. - Management risks are anticipated as the company expands its business scope, necessitating optimization of organizational structure and talent management[140]. - The pharmaceutical industry is undergoing significant transformation, with increasing regulatory standards and market consolidation, presenting both challenges and opportunities for the company[35]. Governance and Shareholder Relations - The company has a board of directors consisting of 7 members, including 3 independent directors, which complies with legal and regulatory requirements[149]. - The company emphasizes transparency in information disclosure, utilizing multiple platforms to enhance investor relations[153]. - The company ensures equal treatment of all shareholders, particularly minority shareholders, during voting processes[148]. - The company has not engaged in any related party transactions that could harm the interests of shareholders[157]. - The company has maintained a rigorous approach to governance, adhering to laws and regulations throughout its operations[178]. Employee Management and Compensation - The total number of employees at the end of the reporting period was 1,140, with 739 in production, 182 in technical roles, and 21 in sales[184]. - The company has implemented a performance-based compensation system, aligning employee salaries with market standards and company performance[185]. - A systematic employee training plan was established to enhance employee skills and overall company competitiveness, including various training programs[186]. - The total remuneration for the board of directors, supervisors, and senior management in 2021 amounted to 4.2615 million RMB[171]. Future Outlook - The financial outlook for the upcoming year remains positive, with expectations for continued growth in revenue and market share[165]. - Future growth opportunities are anticipated in the advanced manufacturing sector of pharmaceuticals, particularly in raw materials and high-quality generics[130].